The value of generic medicines

26 November 2015

Policy

Read more about the value of generic medicines PDF version or […]

EGA-EBG Considerations on WHO’s BQ Proposal – Suzette Kox, WHO INN Open Session with Stakeholders, Geneva, 13 October 2015 (PPT)

13 October 2015

Policy

Investing in People Centred Health Service Delivery – Paul Cornes, Riga Health Conference – How to Improve Health Systems Through Technology? 29-30 June 2015, Riga, Latvia (PPT)

29 June 2015

Policy

Launch of European Value Added medicines (EVA), a new EGA sector group, will deliver efficiency

12 June 2015

Policy

Brussels – The European Generic and Biosimilar medicines Association (EGA) announced […]

EMA & Biosimilar Update: Trends from marketing authorisation applications, scientific advice procedures and policies – Peter Richardson, EBG Biosimilars 2015, London (PPT)

24 April 2015

Policy

The Science of Extrapolation – Martina Weise, EBG Biosimilars 2015, London (PPT)

23 April 2015

Policy

To view the full presentation, please click here. Part I […]

Considerations on WHO’s BQ Proposal – Joerg Windisch, 60th INN Consultation WHO, Geneva, 13 April 2015 (PPT)

13 April 2015

Policy

French Parliament Public Hearing on Biosimilar Medicines, Paris, 29 January 2015 – Intervention from EMA Spokesperson Camille Vleminckx

29 January 2015

Policy

Labelling & Naming – EBG Perspective, DIA Berlin 2014

3 December 2014

Policy

WHO BQ Proposal – EGA’s perspective, 59th INN Consultation, WHO, Geneva, 14 October 2014

14 October 2014

Policy